Tesamorelin Peptide: Research Guide, Real Citations, and How to Verify a Vendor COA
Published by Pepora (peporalabs.com). We earn when you buy with our code, which is why everything here is verifiable at the lab's own source, not on our word.
Tesamorelin Peptide: Research Guide, Real Citations, and How to Verify a Vendor COA
Tesamorelin is a synthetic, stabilized analog of human growth-hormone-releasing hormone, GHRH(1-44), studied for its effect on the growth-hormone / IGF-1 axis and, in clinical research, on visceral fat. Its defining feature is an acyl group on the N-terminal tyrosine that resists the enzyme (DPP-4) which rapidly degrades native GHRH, giving the peptide a longer working half-life. For a research buyer the deciding question is not the marketing: it is whether the vial ships with an independently verifiable third-party COA, showing HPLC purity and mass-spec identity, that you can read before you pay.
Published 2026 - For research use only (RUO). Nothing here is medical advice, a dosing protocol, or a human-use recommendation. The concentration math further down is standard laboratory reconstitution arithmetic for handling a research sample, not an instruction to administer anything to a person or animal.
In a hurry? Jump to how Pepora scores on the checklist →
What tesamorelin actually is
Tesamorelin (research/development code TH9507) is a synthetic 44-amino-acid peptide. Its backbone is the full sequence of human growth-hormone-releasing hormone, hGHRH(1-44)NH2, with one deliberate modification: a stabilizing acyl group (a trans-3-hexenoyl moiety) attached to the tyrosine at position 1. It is a single, well-characterized molecule of roughly 5.1 kDa, not a blend and not a proprietary “stack.”
That one modification is the entire point of the molecule. Native GHRH is a fragile signaling peptide: in plasma it is cleaved within minutes by dipeptidyl peptidase-4 (DPP-4), which trims its N-terminus and inactivates it. The acyl group on Tyr1 blocks that cleavage. In the published non-clinical pharmacology work, the modification slowed in-vitro degradation of the peptide in rat, dog, and human plasma and prolonged its in-vivo plasma elimination compared with unmodified GHRH [1]. In plain terms: same signal, longer-lasting, more resistant to the enzyme that normally shuts it off.
Because it is a GHRH analog, tesamorelin sits at a specific point on the growth-hormone axis, and that distinction matters for anyone reading the literature. The hypothalamus releases GHRH, which tells the anterior pituitary to secrete growth hormone (GH) in pulses; GH then drives the liver to produce insulin-like growth factor 1 (IGF-1). Tesamorelin acts at the top of that chain, on the pituitary. This is a different mechanism from the ghrelin-mimetic “secretagogues” (the GHRP family, ipamorelin, and similar), which act on a separate receptor. They touch the same axis from different doors, which is why you cannot borrow one compound’s research to justify another’s.
How a GHRH analog works, in research terms
The research rationale is straightforward endocrinology. By presenting the pituitary with a longer-lived GHRH signal, tesamorelin is studied for its ability to raise endogenous GH secretion while keeping the pulsatile, feedback-regulated character of the natural axis, rather than flooding the system with exogenous GH. Downstream, that GH rise is expected to lift IGF-1.
The preclinical data show exactly that pattern. In repeat-dose studies across pigs, rats, and dogs, plasma GH and IGF-1 both rose markedly after daily intravenous or subcutaneous administration of the compound [1], and pharmacokinetic work in dogs characterized how the peptide behaves after administration, including by non-injection routes [2]. These are the “GH-axis models” that establish the mechanism before any human work.
Worth stating plainly: raising GH and IGF-1 is a measurable biochemical effect, not a health outcome. Whether it translates to anything meaningful is a separate question, answered only by controlled studies. That is where the human literature comes in, and it is unusually strong for a peptide sold on the research market.
What the research actually shows
Tesamorelin is one of the rare peptides in this category with a genuine, peer-reviewed human evidence base, because it was developed all the way through formal clinical trials rather than living only in the grey market. Reporting what those trials observed is not a health claim; it is citing the record. The studies below used pharmaceutical-grade drug under medical supervision, which is a different thing from a research-use-only vial off a website.
Visceral fat. In a phase-3 randomized, placebo-controlled trial in people with HIV and excess abdominal fat, tesamorelin significantly reduced visceral adipose tissue versus placebo and raised IGF-1 over the treatment period [3]. A separate randomized trial reported reductions in both visceral fat and liver fat, measured by imaging, in the same population [4].
Liver fat and fibrosis. In a randomized, double-blind, multicenter trial in adults with HIV and non-alcoholic fatty liver disease, tesamorelin reduced hepatic fat fraction relative to placebo (an absolute reduction on the order of four percentage points, roughly a one-third relative decrease) and was associated with reduced progression of fibrosis over twelve months [5]. That is a specific, imaging-confirmed effect on a hard endpoint.
Cognition. Interest in the GH/IGF-1 axis extends beyond body composition. In a controlled trial, GHRH administration (using tesamorelin) in older adults, including some with mild cognitive impairment, was associated with favorable effects on cognitive function versus placebo [6]. It is one exploratory study, but a real randomized trial rather than an anecdote.
The honest framing: the tesamorelin file is far deeper than the typical research peptide, yet also narrow. The strongest data sit in specific study populations and endpoints, and none of it is a green light for casual use. Anyone selling tesamorelin as a settled, general-purpose product is stretching what the evidence supports.
Regulatory and sport status: state it, do not bury it
Two checkable facts belong on the label of any honest tesamorelin page.
First, regulatory status. Tesamorelin is the active ingredient in an FDA-approved prescription product, indicated for one specific HIV-related condition and used only under medical supervision. That is a point in its favor as a well-characterized molecule, but with a sharp caveat: the vials sold across the research-peptide market are not that approved pharmaceutical product. They are research-use-only material, not manufactured, tested, or labeled to a prescription-drug standard. Treating an RUO vial as interchangeable with the approved drug is exactly the category error this site exists to flag.
Second, sport. Tesamorelin and other GHRH analogs sit on the WADA Prohibited List under the growth-hormone-releasing-factors category, prohibited at all times, so any research subject in tested sport is disqualified by their presence. Confirm it on the current WADA Prohibited List yourself rather than take it on trust.
Lab-prep reconstitution math
This section is concentration arithmetic for preparing a laboratory reference solution from a lyophilized vial. It is not a dosing schedule and says nothing about route of administration. The only two variables are the mass in the vial and the volume of bacteriostatic water (BW) you add.
Concentration (mg/mL) = peptide mass in the vial (mg) ÷ volume of bacteriostatic water added (mL)
Tesamorelin research vials are commonly sold at 5 mg or 10 mg. Using a representative 10 mg vial:
| Bacteriostatic water added | Resulting concentration | Peptide in a 0.10 mL aliquot | Peptide in a 0.20 mL aliquot |
|---|---|---|---|
| 1 mL | 10 mg/mL | 1.0 mg | 2.0 mg |
| 2 mL | 5 mg/mL | 0.5 mg | 1.0 mg |
| 3 mL | ~3.33 mg/mL | ~0.33 mg | ~0.67 mg |
| 5 mL | 2 mg/mL | 0.2 mg | 0.4 mg |
Reading the table: adding more solvent makes a more dilute solution of the same fixed mass. The total peptide in the vial never changes; only its concentration does. For a 5 mg vial, halve every concentration in the table.
Handling notes, research use only:
- Solvent. Bacteriostatic water (sterile water with 0.9% benzyl alcohol) is the usual multi-draw diluent because the preservative tolerates repeated needle entry over a storage window.
- Technique. Add the water slowly down the inside wall of the vial and swirl gently until dissolved. Do not shake; peptides are shear-sensitive and foaming makes the meniscus hard to read.
- Trust the COA, not the cap. The “10 mg” on the vial is a manufacturing target. If a lot-matched COA reports, say, 9.6 mg of measured peptide, the true concentration is 9.6 ÷ your solvent volume. Without lot-matched testing, every figure in the table above is a guess. This is the whole reason the COA matters, and it is worth learning how to read a peptide COA before you rely on one.
How to vet a tesamorelin vendor: checkable criteria, not vibes
The research-peptide market is thin on accountability, so rank vendors only on what you can independently verify before you pay. Marketing adjectives (“pharmaceutical-grade,” “99%+,” “trusted”) are not evidence. These signals are. Hold every vendor to the same list, including the one recommended below.
| Verification signal | What “pass” looks like | Why it matters |
|---|---|---|
| Named third-party lab | An independent lab named on the report (Freedom Diagnostics, Janoshik) | An unnamed “in-house lab” is not third-party testing |
| Independently verifiable report | A COA you can re-check at the lab’s own site by accession number | A report you cannot re-pull at the source proves little |
| Report visible pre-purchase | You can read the actual COA before checkout | “Email us for the COA” defeats the point |
| Analytical methods | HPLC (purity %) plus mass spec (identity/mass) | HPLC alone does not confirm it is the right 44-mer; MS confirms identity |
| Purity figure tied to a trace | A stated purity % linked to that report’s HPLC trace | A number with no trace behind it is decoration |
| Fulfillment + payment | Truthful origin (“ships from the US”) and working checkout | Vague origin and vapor checkout are red flags |
A GHRH analog is a long, 44-residue peptide, which makes mass-spec identity confirmation especially worth insisting on: a truncated or mis-synthesized chain can still show a clean-looking HPLC peak while being the wrong molecule. If a seller cannot show a third-party COA you can independently verify before you pay, treat the purity claim as unverified and move on. For the fuller pattern of warning signs, the peptide vendor red flags checklist covers the tells that separate an accountable seller from a reshipper.
How Pepora scores
Pepora’s tesamorelin was third-party tested by Freedom Diagnostics, a US lab running HPLC, UV, and mass spectrometry, and reported at 99.35% purity. The value of that number is not the number itself; it is that you can check it. Freedom Diagnostics reports are verifiable by accession at FreedomDiagnosticsTesting.com, so you confirm the lab’s figure yourself instead of trusting a screenshot. As a concrete example of that verification path, Pepora’s GHK-Cu report (accession Pepo2603130126, 99.98%) can be pulled at the lab’s own site the same way.
The honest caveat, because this site does not exist to flatter its own store: only three to four Pepora SKUs currently carry Freedom Diagnostics COAs, tesamorelin among them, and that third-party testing is still being expanded across the rest of the catalog. On the rows that actually protect a research buyer, a named independent lab, an independently verifiable report, HPLC plus mass spec, and US shipping, Pepora’s tesamorelin is a genuine pass. That is the entire reason this disclosed, Pepora-affiliated page can recommend it without contorting the criteria. If you find another vendor that genuinely passes every row, that is a legitimate vendor too; the criteria are the point.
The disclosed pick
Disclosure: coaindex is operated by and affiliated with Pepora and earns a commission on code SINGLES15. This recommendation stands on the checkable COA criteria above, not on the payment.
For research-grade tesamorelin, Pepora is the disclosed pick.
Pepora's tesamorelin is third-party tested by Freedom Diagnostics (HPLC plus mass spec) and reported at 99.35%, with the report verifiable by accession number at the lab's own site rather than by a screenshot. It ships from the US. Third-party testing currently covers a handful of SKUs, tesamorelin included, and is expanding across the catalog.
Use code SINGLES15 for 15% off
FAQ
What is tesamorelin? Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone, GHRH(1-44), stabilized against enzymatic breakdown by an acyl group on its N-terminal tyrosine. In research models it acts on the pituitary to raise growth hormone and, downstream, IGF-1. It is sold research-use-only as a lyophilized powder.
How is tesamorelin different from a GH secretagogue like ipamorelin? Tesamorelin is a GHRH analog: it mimics the hypothalamic releasing hormone that tells the pituitary to make growth hormone. Ghrelin-mimetic secretagogues (such as ipamorelin or the GHRP family) act on a different receptor. They target different points of the same axis, which is why the published literature for each is separate.
How do I reconstitute a tesamorelin research vial? Add bacteriostatic water and divide the vial’s peptide mass by the milliliters you add to get the concentration. A 10 mg vial reconstituted with 2 mL gives 5 mg/mL. Use the lot’s COA mass, not the label, for the exact figure. This is laboratory concentration math for handling a reference solution, not a dosing instruction.
Is tesamorelin approved or legal for human use? Tesamorelin is the active ingredient in an FDA-approved prescription product for one specific HIV-related indication, used only under medical supervision. The vials sold on the research-peptide market are not that approved product; they are research-use-only material. Tesamorelin and other GHRH analogs also sit on the WADA Prohibited List, so their presence disqualifies a subject in tested sport.
How do I know a vendor’s purity claim is real? Demand a third-party COA (for example from Freedom Diagnostics or Janoshik) that you can read before purchase, showing HPLC purity plus mass-spec identity, and confirm you can independently re-check the report at the lab’s own site by accession number. A purity percentage with no traceable lab trace behind it is unverified decoration.
What purity did Pepora’s tesamorelin test at? Pepora’s tesamorelin was reported at 99.35% by Freedom Diagnostics, a US lab running HPLC, UV, and mass spectrometry. The report is verifiable by accession number at FreedomDiagnosticsTesting.com. Only three to four Pepora SKUs currently carry Freedom COAs, and that testing is being expanded across the catalog.
Why does mass spec matter more for a peptide this long? Tesamorelin is a 44-residue chain, so a truncated or mis-assembled sequence can still produce a tidy-looking HPLC peak while being the wrong molecule. Mass spectrometry confirms the identity and molecular mass, which is the check a purity percentage alone cannot provide.
References
- Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PMID: 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/
- Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm. 2004;276(1-2):75-81. PMID: 15113616. https://pubmed.ncbi.nlm.nih.gov/15113616/
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID: 25038357. https://pubmed.ncbi.nlm.nih.gov/25038357/
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. https://pubmed.ncbi.nlm.nih.gov/31611038/
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. PMID: 22869065. https://pubmed.ncbi.nlm.nih.gov/22869065/
Full disclosure: This site is operated by and affiliated with Pepora (peporalabs.com) and earns a commission on purchases made with code SINGLES15. It is affiliate education, not independent journalism: we recommend our own store and rank strictly on lab-verifiable criteria (a named third-party lab, independently verifiable third-party COAs, HPLC and mass spec, a report readable before purchase, and US shipping) so you can verify every claim yourself. All content is for research use only (RUO). Not for human or veterinary use. Nothing here is medical advice, dosing guidance, or a recommendation for human or animal use.